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Abstract: Alcohol misuse represents worldwide an important risk factor for death and disability. Excessive 
alcohol consumption is widely diffused in different ethnicities and alcohol use is part of the lifestyle of both 
young and old people. The genetic basis of alcohol dependence concerning ethanol metabolism and the path-
ways of reward circuits are well known. The role of genetic variants in the neurobiology of addiction as well 
as in response to medication in alcoholism therapy still represents an intriguing argument that needs to be deeply analyzed 
and explained. The molecular approach to the study of these aspects could be difficult because of the large number of 
genes and variations involved. Our work is intended to offer an overview of genes and variants involved in alcohol addic-
tion and pharmacogenetics. Our aim is to delineate a molecular approach strategy to look at alcohol dependence from a 
genetic and applicative point of view. The indications provided in this work should be of help for those who wish to un-
dertake a molecular study of this multifactorial disease. 
Keywords: Alcohol addiction, genetic variants, neurobiology, pharmacogenetics, SNPs, therapy. 
INTRODUCTION 
Alcohol misuse is universally considered a huge prob-
lem. Excessive alcohol consumption is widely diffused in 
different ethnicities, from young to old people, and repre-
sents an important risk factor for death and disability. In the 
recently revised Diagnostic and Statistical Manual of Mental 
Disorders [1], a single category of alcohol use disorders 
(AUD) is now present instead of alcohol abuse and alcohol 
dependence (AD) which were considered separately. Proc-
esses involved in AUD are located mainly in the brain and 
depend upon complex interactions between genes and the 
environment. As shown in many studies that have taken into 
consideration families, twins and adoptive sons, the genetic 
component accounts for at least 60% of the risk factors [2-4] 
and also the quantity of alcohol consumed, frequency of 
drinking, risk of toxicity as well as the response to medica-
tion seems to be genetically controlled. Nowadays molecular 
genetics studies are focalized on biochemical pathways of 
neuronal circuits of reward, addiction and satisfaction in 
addition to studies on biochemical pathways of alcohol me-
tabolism. These latter are of great importance not only for 
alcohol dependence but also for tumorigenesis mediated by 
intermediate products of alcohol metabolism [5] and for risk 
of myocardial infarction and of coronary artery disease [6]. 
The tuning of neurocognitive, behavioral and psychosocial 
aspects of alcohol abuse has led us to pay closer attention to 
new candidate genes that rule alcohol susceptibility and re-
sponse to pharmacological treatment. As examples, the μ 
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opioid receptor gene (Oprm1), that encodes for the μ opioid 
receptor, is involved in reward and emotional pathways and 
in the pharmacological response to the receptor antagonist 
naltrexone. The solute carrier family 6 member 4 (Slc6a4) 
gene, encoding for the serotonin transporter, is the molecular 
target of many antidepressants (serotonin reuptake inhibi-
tors) and is also linked to major depressive disorders. 
Gamma-aminobutyric acid receptor (Gabr) genes, that en-
code for the subunits of the GABA (gamma-aminobutyric 
acid) receptor, are strongly associated with severe alcohol 
addiction. Alcohol compromises also glutamatergic trans-
mission by affecting the functions of ionotropic and of me-
tabotropic glutamate receptors. Solute carrier family 6 mem-
ber 3 (Slc6a3) (dopamine transporter), dopamine receptor D2 
(Drd2) and dopamine receptor D4 (Drd4) genes, that regu-
late the release and synthesis of dopamine, have strong ef-
fects on mechanisms of reward that correlate with alcohol 
consumption. All these genes affect neurobiology of cogni-
tive functions, anxiety, depression, reward and neuronal 
plasticity in response to alcohol administration. A large 
number of association studies are ongoing to consolidate 
data and provide new molecular markers of dependence in 
order to define genotype-phenotype relationships and per-
sonal therapeutic strategies. The sequence variations in-
volved are, in most cases, single nucleotide polymorphisms 
(SNPs) whereas, in other cases, are a variable number of 
tandem repeats (VNTR) that could confer susceptibility or 
protection in response to alcohol administration. Genome 
wide association studies (GWAS) together with candidate 
gene approaches have already delineated a large number of 
molecular targets possibly related to a genetic predisposition 
to alcohol abuse and addiction [7]. GWAS focusing on this 
argument will be reviewed later on this paper as well as pros 
and cons related to this powerful approach. The comparison 
 1875-533X/15 $58.00+.00 © 2015 Bentham Science Publishers 
Be
nth
a
 S
ien
ce
 P
ub
lis
ers
 
Fo
r P
rso
na
l U
se
 O
nly
 
No
 F
r D
ist
rib
uti
on
Alcohol Addiction: A Molecular Biology Perspective Current Medicinal Chemistry, 2015, Vol. 22, No. 6    671 
between a target and a matched control population, for a 
single or a set of DNA sequence variations, provides robust 
information about the relevance of the variations analyzed. 
More powerful information can be retrieved if a correct lay-
ering of patients is done, especially for alcoholism where 
behavioral, social and biological features are contemporarily 
involved. Unfortunately, the usefulness of these approaches 
is often limited by the small size of case series and by the 
consequent reduced power of statistical approaches. 
The biological aspects of alcohol addiction are extremely 
various, here we describe genetic variants that concern the 
genes involved in metabolizing alcohol pathways as well as 
those involved in neural transmission and implicated in the 
pathogenesis and treatment of alcoholism. This paper is in-
tended to offer an overview of those sequence variations in-
volved in alcohol addiction mechanisms, with the aim to de-
lineate a molecular approach strategy to look at alcohol de-
pendence from a genetic and applicative point of view. The 
indications provided should be of help for those who wish to 
undertake a molecular study of this multifactorial disease.  
MOLECULAR BIOLOGY OF ALCOHOL METABO-
LIZING ENZYMES 
The liver metabolizes circulating alcohol mainly in two 
successive steps: alcohol dehydrogenase (ADH) catalyzes 
the reversible oxidation of ethanol to acetaldehyde and alde-
hyde dehydrogenase (ALDH) transforms the acetaldehyde 
produced in acetic acid. 
The following paragraphs use the new nomenclature for 
the human alcohol dehydrogenase as described in the work 
of Duester and colleagues [8]. 
In Table 1 the organization and the characteristics of the 
genes related to alcohol metabolizing enzymes, are shown. 
In Table 2 a concise list of all point variations described in 
the sections below is provided. 
Alcohol Dehydrogenase (ADH) 
Alcohol dehydrogenase is a member of the MDR (Me-
dium chain reductase/dehydrogenase) family of proteins. 
Five different classes of ADH exist in humans. This protein, 
formed by two subunits, can exist as a homo- or hetero-
dimer. Seven different genes cluster in the chromosome 4q 
region and code for the monomers. The class I ADH is 
mainly involved in alcohol metabolism of humans. Subunits 
named ?, ? e ?, which share more than 93% of sequence 
homology [9], combine to form homo- and hetero-dimers 
and are encoded respectively by Adh1a, Adh1b and Adh1c 
genes. Sequence variations of Adh1b produce three different 
subunits: ?1, ?2 and ?3. Two polymorphisms occurring re-
spectively at position 48 (p.Arg48His - rs1229984) and at 
position 370 (p.Arg370Cys - rs2066702) of the polypeptide 
chain of the ? subunit, define the Adh1b*1 (48Arg-370Arg), 
*2 (48His-370Arg) or *3 (48Arg-370Cys) allele. The geno-
types Adh1b*1/Adh1b*2 (?1/?2) and the Adh1b*2/Adh1b*2 
(?2/?2) produce an enzyme up to 100 times faster than the 
Adh1b*1/Adh1b*1 (?1/?1) genotype [10]. These well-known 
risk loci were recently confirmed in the largest sample for 
AD GWAS to date by Gelernter et al [11]. Adh1b*2 allele 
was found to be protective in association with Aldh2 Lys504 
allele (p.Glu504Lys - rs671) in a Korean population of 1032 
individuals [12]. The presence of both the alleles Arg48 and 
Glu504 confers a greater susceptibility for AD if compared 
to the presence of one or none of the risk alleles. In a recent 
GWAS performed in a large sample of Korean AD subjects, 
Park and colleagues found that the Adh1b rs1229984 poly-
morphism has a significant association with AD (with the 
Arg48 as the risk allele) and that this variation could be the 
only functional genetic marker in the ADH gene cluster [13]. 
The Adh1b*3 allele was found mainly in African lineage 
population [14]. This polymorphic allele seems to have a 
protective role with a reduced risk for alcohol dependence 
[15-17]. Higher level of sedation in Adh1b*3 carriers after 
alcohol administration [18] or, as otherwise supposed, the 
faster elimination of ethanol that leads to higher levels of 
acetaldehyde are responsible for adverse effects after alcohol 
consumption. The subunit ?1 (Adh1b*1) carrying no varia-
tion at both sites results in a wild type protein. Adh1c give 
rise to Adh1c*1 and Adh1c*2 subunits depending on two 
polymorphic sites, one in exon 6 (p.Arg272Gln; rs1693482) 
and the other in exon 8 (p.Ile350Val; rs698). Adh1c*1 and 
Adh1c*2 represent two different haplotypes, 272Arg-350Ile 
and 272Gln-350Val respectively, arising from the above 
mentioned polymorphisms which are known to be in strong 
linkage [18]. The Adh1c*1 variant in homozygosis was de-
scribed as protective about alcohol addiction if compared to 
Adh1c*2, heterozygotes and homozygotes, in Asian popula-
tions [19,20]. The Adh1c*2 variant shows a slight associa-
tion with alcohol dependence in European populations; this 
may be due to a linkage of this variation with Adh1b in some 
ethnic groups [21]. Class II ADH, as well as class III, only 
exists as a homodimer. Class II alcohol dehydrogenase con-
tributes to alcohol metabolism in the liver at high concentra-
tion, its role in alcoholism is still under investigation. Many 
polymorphisms of the Adh2 gene seems to be involved in 
alcohol dependence [15,22-24] but with divergent results in 
different populations. The c.-136A>C (rs 1800759) in the 
promoter region of Adh2 gene seems to be the most interest-
ing among sequence variations studied with the C allele as-
sociated with a lower activity of the ? subunit. Another SNP 
(rs1042364) occurring at exon 9 causes an aminoacid substi-
tution (p.Gly388Arg) that might also affect the function of 
the ? subunit. Results from large multicenter association 
studies confirm the significant relationship of Adh2 variants 
with an AD phenotype. The effect is of a predisposition to 
AD that explicates itself in a recessive manner and in spe-
cific populations, but with a lower impact if compared with 
functional variants of other alcohol or acetaldehyde-
metabolizing enzymes [23,24]. The remaining ADH classes 
seem not to be involved in alcohol use disorders.  
Aldehyde Dehydrogenase (ALDH) 
The human genome contains 19 Aldh genes whose prod-
ucts participate in oxidizing a large number of endogenous and 
exogenous aldehydes. Aldh1a1, which is in the cytosol, and 
mitochondrial Aldh2, mainly contribute to the metabolism of 
acetaldehyde in vivo. The Aldh2 gene has a polymorphic locus 
on exon 12 that causes an amino acid change from glutamic 
acid to lysine at the 504
th
 position of the polypeptide chain 
(p.Glu504Lys - rs671) due to a G to A change in the nucleo-
tidic sequence. The A allele (Aldh2*2) encodes an inactive 
subunit with an impaired ability to metabolize acetaldehyde.  
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Table 1. Organization and characteristics of genes related to alcohol metabolizing enzymes involved in alcohol dependence. 
Enzyme Class Gene Allele 
Variation 
Type 
Subunit Position 
Estimated 
Length (Kb) 
N° of  
exons* 
Transcripts 
Adh1a - - ? 4q23 14.7 9 3 
Adh1b*1 
SNP 
combination 
?1 
Adh1b*2 
SNP 
combination 
?2 Adh1b 
Adh1b*3 
SNP 
combination 
?3 
4q23 16.4 9 5 
Adh1c*1 
SNP 
combination 
?1 
I 
Adh1c 
Adh1c*2 
SNP 
combination 
?2 
4q23 16.5 9§ 4 
II Adh2 - SNPs ? 4q23 20.6 9 12 
III Adh3 - - ? 4q23 17.7 9 12 
IV Adh4 - - ? 4q23 23.2 9 6 
ADH 
V Adh5 - - - 4q23 16.6 9 8 
Aldh1a1*2 17bp del - 
Aldh1a1 
Aldh1a1*3 3bp ins - 
9q21.13 52.4 13 7 
ALDH 
Aldh2 Aldh2*2 SNP - 12q24.12 43.1 13 4 
*The number of exons and the estimated length are referred to the longest transcript of the single gene registered in the Consensus CDS project (or to the longest transcript if no 
Consensus CDS registered sequence is available). 
§no Consensus CDS sequence available. 
 
Table 2. Single nucleotide polymorphisms of genes related to alcohol metabolizing enzymes involved in alcohol dependence. 
Gene rs/HGMD Accession 
Nucleotide Change 
(Forward Strand) 
Aminoacid Change 
(Codon) 
Allelic Frequencies 
(Overall, 1000 Genomes) 
rs1229984 T/C p.Arg48His T (0.21)/C (0.79) 
Adh1b 
rs2066702 G/A p.Arg370Cys G (0.95)/A (0.05) 
rs1693482 C/T p.Arg272Gln C (0.76)/T (0.24) 
Adh1c 
rs698 T/C p.Ile350Val T (0.76)/C (0.24) 
rs1800759 T/G n. c. T (0.46)/G (0.54) 
Adh2 
rs1042364 T/C n. c. T (0.14)/C (0.86) 
Aldh2 rs671 G/A p.Glu504Lys G (0.94)/A (0.06) 
n. c.= no change 
 
Several polymorphic variants have been identified in the 
promoter region of the Aldh1a1 gene: a 17-bp deletion 
(Aldh1a1*2) and a 3-bp insertion (Aldh1a1*3), even though 
the effect of Aldh1a1 variants on alcohol metabolism and 
alcohol response is still unclear [18,25]. Aldh variants affect-
ing the enzyme function may result in a protective effect for 
alcohol dependence and heavy drinking due to a less effi-
cient breakdown of acetaldehyde and a stronger response to 
alcohol that include the adverse effect of the ‘‘flushing reac-
tion’’. An increased production or an impaired metabolism 
of acetaldehyde produces flushes and blotches associated 
with erythema that appear on the face, neck, shoulders and 
sometimes on the entire body, of individuals that consume 
alcohol because of an accumulation of this toxic product. 
Subjects experiencing the alcohol flush reaction are less 
prone to alcohol addiction (Fig. 1).  
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Fig. (1). The presence of different alleles that code for subunits of alcohol metabolizing enzymes determines the efficiency of trasformation 
of alcohol and acetaldehyde. As a result, an increased production or an impaired metabolism of acetaldehyde produces a "flushing reaction" 
that makes less prone to alcohol consumption. On the other hand, a rapid removal of ethanol and acetaldehyde could instead confer suscepti-
bility to AD. ADH= Alcohol dehydrogenase; ALDH= Aldehyde dehydrogenase; Rabbit= Higher efficiency; Turtle= Lower efficiency. 
 
MOLECULAR NEUROBIOLOGY OF ALCOHOL USE 
DISORDERS 
In Table 3 the characteristics of genes related to neurobi-
ology of alcohol addiction, are summarized. In Table 4 and 
Table 5 a concise list of all point variations and VNTR de-
scribed in the following paragraphs is provided. 
5-Hydroxytryptamine Transporter and Receptors  
Serotonin (5-hydroxytryptamine, 5-HT) has a primary 
role in different functions of the central nervous system, in 
health and disease. Depression, bipolar disorders, anxiety, 
obsessive - compulsive disorders, eating behavior, neurode-
generative disorders and drug addiction depend on serotonin 
trafficking within the brain [26]. Serotonin transport in the 
brain and in specific tissues such as cells and platelets is me-
diated by the serotonin transporter (5-HTT). In the synaptic 
space 5-HTT controls the rapid removal of 5-HT managing 
amplitude, length and spatial distribution of signals that 
reach serotonin receptors [27]. Changes in serotonin trans-
mission are also associated with alcohol dependence [28]. 
Some studies have evidenced that an increase in serotonin 
transmission obtained by blocking 5-HT reuptake with selec-
tive serotonin re-uptake inhibitors (SSRIs), causes a reduc-
tion of alcohol consumption in various animal models [29]. 
In humans, however, lower brain levels of serotonin corre-
late with an augmented use of alcohol [30]. Due to its cen-
trality in serotonin transmission, genetic studies concerning 
5-HT function in alcohol dependence are focused on the 
Slc6a4 gene that codes for 5-HTT [31,32]. Transcriptional 
activity of this gene is modulated by a repeated element of 
variable length in the 5’ flanking region, about 1.4kb up-
stream from the transcription starting site called 5-HTTLPR 
(serotonin-transporter-linked polymorphic region). The S 
(Short) allele is made of 14 repeated elements (each repeated 
element is 20 or 23 nucleotides long), while the L (Long) 
allele is of 16 repeats. Alleles of 15, 18, 20 or 22 repeats are 
less frequently observed. This functional polymorphism has 
been intensively investigated in relation to alcohol addiction 
and even though allelic and genotypic distribution is ex-
tremely variable among different ethnic groups, a recent 
meta-analysis demonstrates a significant but modest associa-
tion between alcohol dependence and the presence of at least 
1 short allele [33]. In healthy humans the L/L genotype have 
an increased 5-HT uptake in platelets and a greater brain 
serotonin binding. Expression analysis performed on human 
lymphoblastoid cells also show that 5-HTT mRNA levels are 
higher in L/L than in L/S or S/S genotypes. Alcohol depend-
ent subjects with L/L variants, compared with healthy indi-
viduals have, on the contrary, reduced [
123
I]2 ?-
carboxymethoxy-3 ?-(4-iodophenyl)tropane (?-CIT) neu-
ronal binding to 5-HTTs in the raphe nuclei of the brain and 
a lower 5-HT uptake in platelets if compared with S/S geno-
type individuals [34]. A SNP in the 3’-untranslated region 
(3’-UTR) of the Slc6a4 gene, the rs1042173, was recently 
associated to severity of drinking [35] and to response to 5-
HT targeting therapy in AD patients. Another functional 
allelic variant (rs25531) in the 5’UTR region of the Slc6a4 
gene, a few bases upstream from the regulatory 5HTTLPR 
region, can also modulate expression of the serotonin trans-
porter. The presence of the G allele (26247A>G) makes the 
L allele as efficient as the lower-activity S allele [36]. These 
two polymorphic regions are commonly described together 
as a tri-allelic polymorphism, with the LA as the “high” ex-
pressing allele and both the LG and S as the “low” expressing 
alleles. In a recent work, Seneviratne and collaborators [37] 
showed that interactive effects of multiple sequence varia-
tions within the single pathway of serotoninergic transmis-
sion at different levels can confer greater susceptibility to 
alcohol dependence than the single variations considered 
alone. They found in alcoholic patients of European descent 
significant interactive effects among variants in the Slc6a4,  
Htr3a and Htr3b genes that encode respectively for the 5-HT 
3A and 3B receptors. The low frequency allele of the SNP 
rs33940208 (T) in Htr3a and of the SNP rs2276305 (A) in 
Htr3b result inversely associated with AD. 
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Table 3. Characteristics of genes related to neurobiology of alcohol dependence. 
Gene Position Estimated Length (Kb) N° of exons* Transcripts 
Slc6a4 17q11.2 41.7 14 5 
Slc6a3 5p15.33 52.6 15 5 
Htr3a 11q23.2 15.2 8 8 
Htr3b 11q23.2 41.9 9 3 
Drd4 11P15.5 3.4 4 2 
Drd2 11q23.2 65.8 8 11 
Drd1 5q35.2 4.2 2 1 
Comt 22q11.21 28.4 6 11 
Gabra2 4p12 226.8 10 15 
Oprm1 6q25.2 69.5 4 23 
Grin2a 16p13.2 424.2 14 11 
Auts2 7q11.22 1190 19 18 
Chrm2 7q33 151.6 3 9 
Chrna3 15q25.1 25.9 6 8 
Chrna5 15q25.1 29.7 6 4 
*The number of exons and the estimated length are referred to the longest transcript of the single gene registered in the Consensus CDS project (or to the longest transcript if no 
Consensus CDS registered sequence is available). 
 
Dopamine Receptors and Transporter 
The dopaminergic system is deeply involved in brain re-
ward circuits and plays an important role in alcohol-related 
behaviors. Neurochemical studies in animal models suggest 
that alcohol administration raises dopamine levels in nucleus 
accumbens and increases neurotransmission in dopaminergic 
neurons of the ventral tegmental area [38-40]. A decreased 
density in striatal dopamine receptors, observed in alcohol 
dependence, is supposed to decrease susceptibility to en-
dogenous effectors of the reward circuits, pushing to alcohol 
abuse in order to compensate this lack of rewarding effect 
[41]. Among the components of the dopaminergic systems, 
the D2 dopamine receptor gene (Drd2) has been studied in 
depth in alcohol dependent subjects. The Drd2 gene has two 
polymorphic alleles that differ according to the presence or 
absence of a restriction site for the TaqI endonuclease 
(rs1800497). The TaqI polymorphism, that was supposed to 
be in the 3’ non coding region of Drd2 gene, was found to be 
instead in the coding region of a neighbor gene, the Ankk1 
(ANKyrin repeat and Kinase domain containing 1) [42]. A 
large number of studies have focused on the relation between 
the Drd2/Ankk1 polymorphism (rs1800497) and alcohol de-
pendence with different results. A meta-analysis performed 
by Lesley Smith and colleagues [43] reports a small effect 
for the association of the A1 allele (T), even though a strong 
association remains in studies that use ethnic-matched con-
trols, or controls screened for alcohol dependency. A strong 
association was recently confirmed in a study conducted in 
280 alcoholic subjects and 280 age- and sex-matched con-
trols from central Italy [44]. The D4 receptor has been stud-
ied as well in relation to alcohol abuse and addiction. Many 
studies have analyzed the exon 3 region of the Drd4 gene, 
where a VNTR of 48 base pairs affects dopamine transmis-
sion. Drd4 VNTR spans from 2 to 11: the longest alleles, 7 
repeats or more, were recently associated in different studies 
with social drinking behavior, but with controversial results. 
A specific haplotype rs686 T allele and rs4532 G allele 
within the Drd1 gene is significantly more frequent in pa-
tients with alcohol dependence, with the T allele of rs686 
largely frequent in patients with severe dependence and even 
more in subjects complicated by withdrawal seizures [45]. 
Dopamine transporter is a sodium/chloride dependent 
transporter, with 12 trans membrane domains, responsible 
for the dopamine reuptake in presynaptic neurons [46]. Do-
pamine transporter is encoded by the Slc6a3 gene. The cod-
ing region of this gene is strongly preserved and the poly-
morphisms found in this area are represented by synonymous 
base changes or sporadic irrelevant amino acid substitutions. 
The genetic polymorphism mainly studied in relation to al-
cohol dependence is a VNTR of 40 bp in the 3’ untranslated 
region of the Slc6a3 gene, with a number of repetitions that 
spans from 3 to 16. Several studies have described this 
polymorphism in relation to AD with controversial results. 
With the intent to clarify the role of the dopamine transporter 
in alcohol addiction two meta-analysis on this argument have 
been recently published. The one by Du and colleagues in-
vestigated the association between the nine repetition allele 
of Slc6a3 and alcoholism, suggesting a possible association 
with a specific subset of patients with alcohol withdrawal 
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Table 4. Single nucleotide polymorphisms associated with the neurobiology of alcohol dependence. 
Gene rs/HGMD Accession 
Nucleotide Change 
(Forward Strand) 
Aminoacid Change 
(Codon) 
Allelic Frequencies 
(Overall, 1000 Genomes) 
rs1042173 A/C n. c. 
A (0.49)/C (0.51) 
Slc6a4 
rs25531 T/C n. c. 
T (0.89)/C (0.11) 
Htr3a rs33940208 C/T n. c. 
C (0.88)/T (0.12) 
Htr3b rs2276305 G/A n. c. 
G (0.87)/A (0.13) 
Drd2 rs1800497/CM041241 G/A p.Glu713Lys 
G (0.70)/A (0.30) 
+rs686/CR082013 G/A n. c. 
G (0.38)/A (0.62) 
Drd1 
+rs4532/CR004740 C/T n. c. 
C (0.25)/T (0.75) 
Comt rs4680/CM960420 G/A p.Val158Met 
G (0.61)/A (0.39) 
rs279826 A/G n. c. 
A (0.50)/G (0.50) 
rs279836 T/A n. c. 
T (0.58)/A (0.42) 
rs279858 T/C n. c. 
T (0.57)/C (0.43) 
Gabra2 
rs279871 T/C n. c. 
T (0.59)/C (0.41) 
Oprm1 rs1799971 A/G p.Asn40Asp 
A (0.81)/G (0.19) 
rs2072450 C/A n. c. 
C (0.88)/A (0.12) 
Grin2a 
rs9924016 G/- n. c. 
G (0.70)/- (0.30) 
Auts2 rs6943555 T/A n. c. 
T (0.66)/A (0.34) 
?rs1824024 C/A n. c. C (0.42)/A (0.58) 
?rs2061174 G/A n. c. G (0.47)/A (0.53) 
?rs324650 T/A n. c. T (0.56)/A (0.44) 
Chrm2 
rs324640 G/A n. c. 
G (0.57)/A (0.43) 
Chrna5 rs615470 T/C n. c. 
T (0.28)/C (0.72) 
Chrna3 rs578776 G/A n. c. 
G (0.46)/A (0.54) 
+rs686 (T) - rs4532 (G) specific haplotype is associated with alcohol dependence - ?the rare rs1824024 (G) - rs2061174 (T) - rs324650 (A) haplotype, was found to be over-
transmitted to alcohol dependent individual; n. c.= no change 
 
seizure or delirium tremens [47]. No association was found 
(in general or in stratified analysis according to the geo-
graphic area, ethnicity, gender, and diagnostic criteria) in a 
pooled analysis of published multicenter case-control stud-
ies, concerning the association between Slc6a3 polymor-
phism and alcohol dependence, performed by Xu and Lin 
[48]. This loss of association was recently confirmed in a 
case-control study performed by Mignini and colleagues on a 
population of central Italy [44]. Lastly, concerning the re-
moval and metabolism of dopamine, several studies have 
shown that a missense mutation (p.Val158Met; rs4680) with 
a functional effect of the catechol-O-methyltransferase 
(Comt) gene is associated with alcohol dependence in men 
[49] and women with smoking comorbidity [50]. However, a 
larger sample analysis by Foroud and colleagues [51] failed 
to replicate this association. A more recent work [41] con-
firms this lack of association between Comt p.Val158Met 
genotype and alcohol dependence, but suggests that this 
variation, affecting dopamine receptor sensitivity at the level 
of the pre frontal cortex, can increase vulnerability to the 
development of alcohol dependence. 
 
Table 5. VNTRs associated with the neurobiology of alcohol 
dependence. 
Gene Name Location VNTR Lenght Repeats 
Slc6a4 5’UTR 20, 23bp 14-16,18,20,22 
Drd4 Exon3 48bp 2-11 
Slc6a3 (Dat1) 3’UTR 40bp 3-16 
 
GABA Mediated Transmission 
Gamma Amino butyric acid (GABA) is the principal in-
hibitory neurotransmitter in the human CNS. Three different 
GABA receptors, called GABA-A, B and C are dissimilar in 
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terms of molecular structure, pharmacology and signal trans-
duction mechanism. GABA-A and GABA-C receptors 
(ionotropic) are ion channels regulating Cl
- 
influx, while 
GABA-B receptors (metabotropic) are G protein coupled 
receptors. The GABA-A receptors are present in the human 
brain mostly as pentameric structures composed of three 
predominant subunits (?, ? and ?) even though different 
forms of GABA-A receptors (e.g. multimers of a single 
subunit) and adjunctive subunits have been described. In the 
adult human brain GABA-A receptors exist mainly as 
?1?2?2 (60%), ?2?3?2 (15%) and ?3?3?2 (10%) [52]. Clus-
ters of genes coding for many of the different GABA-A re-
ceptor subunits are located in chromosome 4p12-p13 
(Gabra2, Gabra4, Gabrb1 and Gabrg1 genes coding respec-
tively for the ?2, ?4, ?1 and ?1 subunits), as well as in 
chromosome 5q31-q35 (?1, ?6, ?2, ?2), in chromosome 
15q11-q13 (?5, ?3, ?3) and in chromosome Xq28 (?3, ?4, 
?1) [53,54]. 
The link between GABA receptor SNPs and alcohol de-
pendence has been previously described by several papers. 
Single nucleotide polymorphisms and overlapping haplo-
types have emerged as feasible risk loci from different stud-
ies concerning Gabra2 and AD subjects from COGA (Col-
laborative Study on Genetics of Alcoholism) samples and 
other independent samplings [54-61], so that for AD in indi-
viduals with European and native American ancestry this 
gene is considered an established risk locus [62,63]. The 
region around exon 5 of Gabra2 gene contains the most rep-
licated haplotypes associated with AD: four SNPs 
(rs279826- rs279836- rs279871- rs279858) seem to be com-
mon in haplotypes related to AD alone [55] and to AD in 
comorbidity with cocaine and marijuana dependence [56]. In 
exon 5, rs279858 cause a synonymous change at amino acid 
number 132 in the polypeptide chain causing a differential 
allele-related mRNA expression as assessed in brain tissue 
from deceased alcoholic individuals [64]. The other varia-
tions composing these haplotypes could rather be involved in 
gene regulation through post-transcriptional mechanisms. 
Other studies have been extended to the adjacent Gabrag1 
gene but with a weaker correlation to AD if compared with 
the Gabra2 gene. 
Opioidergic Transmission 
The Opioid endogenous system undertakes a conspicuous 
number of physiological and neurological functions and also 
seems to perform an important role in the development and 
maintenance of alcohol addiction. Studies in human and 
animal models have shown that alcohol administration in-
creases synthesis of opioid peptides and opiate mediated 
neurotransmission, stimulating an increment in alcohol con-
sumption while opioid antagonists reverse this effect [65]. 
Opioidergic agents are supposed to modulate dopaminergic 
transmission at the mesolimbic pathway and to regulate do-
pamine release in the Nucleus Accumbens. In the early 
1970s several groups, driven by the discovery of the strong 
pharmacological effect led by morphine and its specificity to 
induce neurobiological effect, identified the presence of 
opioid receptors in brain and peripheral tissues. Conse-
quently, there was a contemporary interest in finding en-
dogenous ligand for these receptors. In 1975 Bradbury and 
coworkers discovered the ?-endorphin, derived from the 
precursor proopiomelanocortin [66]. ?-endorphin as well as 
other opioidergic substances can activate different classes of 
opioid receptors (μ, ? and ?) eliciting morphine like effects. 
The μ-opioid receptor is the main site of action of morphine 
and of the most commonly used opioids. The μ opioid recep-
tor, encoded by the Oprm1 gene, shares a high grade of ho-
mology with the other opioid receptors [67]. By sequencing 
DNA from subjects with psychiatric disturbances related to 
the opioid function, Bergen and colleagues identified four 
sequence variations, three in the coding region of the Opmr1 
gene and one intronic [68]. The most relevant was an A to G 
substitution at position 118 (c.118A>G), which codes for the 
p.Asn40Asp substitution (rs1799971). This sequence varia-
tion appeared to be functional and linked to a gain of func-
tion associated to the minor allele [69]. To the contrary, a 
successive work considering this SNP described a loss of 
function rather than a gain, where the G allele produced a 
lowering in protein expression and function [70]. Ramchan-
dani and colleagues, in a more recent study, described, in 
social drinkers examined for striatal dopamine release using 
positron emission tomography and [11C]-raclopride dis-
placement, a striatal dopamine increase after alcohol admini-
stration limited to subjects with the minor G allele. In the same 
study two lines of humanized mouse carrying the human 
Oprm1 c.118A>G A/A or G/G variants were created and brain 
microdialysis of the mouse with the Oprm1 G/G variant 
showed a fourfold greater peak of dopamine response to an 
alcohol challenge compared to those carrying the A/A variant 
[71]. Several studies tried to establish a relationship between 
c.118A>G Oprm1 polymorphism and alcohol and misuse of 
other substances (opiates mainly) with positive [72-74] or 
negative [68,75-79] results in terms of association. 
Glutamatergic Transmission 
Glutamate is the major excitatory neurotransmitter in the 
brain and glutamatergic neurons are prominent in the cere-
bral cortex. Alcohol affects glutamate transmission most 
likely by altering the functions of ionotropic glutamate re-
ceptors (iGluRs) and of metabotropic glutamate receptors, in 
particular subtype 5 receptors (mGluR5) [80]. The N-
Methyl-D-aspartate (NMDA) receptors, the AMPA (?-
Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) re-
ceptors and the Kainate receptors represent the three main 
classes of the iGluRs. Ethanol has, in general, an important 
inhibitory effect on iGluRs and the inhibition of NMDARs, 
that occur at intoxicating levels of ethanol, is widely de-
scribed in literature [81-84]. NMDARs are made of a manda-
tory NR1 subunit together with at least one NR2 or NR3 
subunit. All NMDAR subtypes are inhibited by ethanol but 
receptors with different composition in subunits show differ-
ences in the sensitivity to inhibition. In particular, the inhibi-
tory action of ethanol is enhanced by the presence of the 
NR2B-subunit in NR3-containing receptors [85]. Moreover, 
a large effect of EtOH on NR2B containing NMDARs was 
already seen in different neuronal preparations [86,87]. 
However, a genetic study that analyzed sequence variations 
in glutamatergic neurotransmission genes showed that Nr2a 
(also known as Grin2a) and Mglur5 were the most powerful 
predictors of human alcohol dependence among the genes 
selected, even though, a subsequent replication analysis 
study confirmed the association of alcohol dependence only 
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for Nr2a (odds ratio, 2.01) [88]. The Nr2a variations in-
volved were a C-to-A substitution in rs2072450 (intron 11) 
and a deletion/insertion in rs9924016 (intron 7) and the risk 
genotypes were rs2072450 C/C and rs9924016 Del/Del. A 
more recent gene-set analysis approach performed by 
Karpyak and colleagues [89] using SNP data from the Study 
of Addiction: Genetic and Environment (SAGE) [90], 
showed an association between alcohol dependence and 
variation in the NMDA-dependent AMPA receptor traffick-
ing cascade. Part of this molecular pathway is the cal-
cium/calmodulin-dependent protein kinase II (CaMKII), this 
protein plays a key role in memory formation and recently 
has been increasingly involved in the development of drug 
addiction. In a recent work autophosphorylation deficient 
?CaMKII (T286A) mice showed an accelerated conditioned 
place preference (CPP) compared to wild type (WT) mice 
suggesting a difference between the two groups in the nega-
tive reinforcing properties of alcohol [91]. Unexpected mo-
lecular targets concerning glutamatergic system function 
derived from a genome-wide association study meta-analysis 
performed by Schumann et al. [92]. The authors selected few 
polymorphisms that reached genome-wide significance from 
about 2.5 million directly genotyped or imputed SNPs with 
alcohol consumption in 26,316 individuals of European an-
cestry. Of the seven SNPs tested, only rs6943555 in autism 
susceptibility candidate 2 gene (Auts2) was associated with 
alcohol consumption at genome-wide significance. From the 
above mentioned study a variation in the ras-specific gua-
nine-nucleotide releasing factor 2 (Rasgrf2) gene was further 
investigated by Stacey and co-workers [93]. It is well known 
that NMDA receptors and Ras-ERK signaling have a consis-
tent role in alcohol-induced plasticity. Rasgrf2, a gene re-
lated to glutamatergic transmission, links NMDA receptors 
to the activation of the Ras-ERK signaling cascade. Pharma-
cological and genetic approaches, used to investigate the role 
of the Ras-ERK pathway and downstream gene expression in 
the striatum, lead to the hypotesis that an abnormal hyperac-
tivation of Ras-ERK, which conduces to an hyper-
glutamatergic state, seems to be a key pathogenic factor for 
addictive behaviour [94,95]. 
Acetylcholine Mediated Transmission 
Early researches on how ethanol affects cholinergic 
transmission are based on the observation that alcohol drink-
ing is often associated with cigarette smoking. A recent work 
by Vink and collaborators support this idea revealing many 
common variants, with a very small individual effect size, 
influencing smoking behavior, alcohol and cannabis use 
[96]. Acetylcholine, synthesized from choline by the enzyme 
AcetylCoA cholineacetyltransferase (ChAT) (Ach), was the 
very first neurotransmitter to be identified back in the early 
1900s and its distribution in the CNS was found to be similar 
to that of the neurotransmitter GABA. The Ach receptors 
system is made of two main components: the muscarinic and 
the nicotinic receptors. Muscarinic receptors are G protein 
coupled receptors while nicotinic receptors are ligand-gated 
ion channels. 
Five subtypes of muscarinic receptors exist, from M1 to 
M5, coded by just as many genes. At least 17 different 
subunits (?1-?10; ?1-?4; ?; ?; ?) are differently arranged to 
compose the pentameric structure of brain and muscle nico-
tinic receptors. Brain nicotinic receptors are formed by an 
arrangement of ? and ? subunits only. Genes for the ? 
subunits are named from Chrna1 to Chrna10 and for the ? 
subunits from Chrnb1 to Chrnb4. Chrna1 and Chrnb1 genes 
code for muscle-type ?1 and ?1 subunits respectively. 
Past linkage studies showed a relationship between cho-
linergic muscarinic receptor-2 (Chrm2), located on the long 
arm of chromosome 7, and alcohol dependence [97,98]. 
More recently, polymorphisms of the Chrm2 gene have been 
associated with alcohol dependence and major depressive 
syndrome [99]. Wang and colleagues using COGA samples 
have found several SNPs associated with alcohol dependence 
in the Chrm2 gene, in particular, three SNPs with a strong 
association: rs1824024 in intron4, rs324640 and rs324650 in 
intron 5. The authors also performed a haplotype analysis 
finding three SNPs (rs1824024-rs2061174-rs324650) that 
form three common haplotypes: T-T-T, G-C-A and T-T-A 
that represent 80% of the observed haplotypes. The common 
T-T-T haplotype (>43%) is under-transmitted to alcohol de-
pendent individuals while the rare G-T-A haplotype, is in-
stead over-transmitted. These findings were confirmed also 
by other researchers [100]. A recent work by Jung and col-
leagues [101] describes results from a moderate sized sample 
of Korean control and AD subjects examining the associa-
tion of Chrm2 polymorphisms and alcohol dependence. They 
found a marginal association of SNP rs324650 with the risk 
of alcohol dependence but a significant association of SNP 
rs1824024 with the AUDIT (Alcohol Use Disorders Identifi-
cation Test) and ADS (Alcohol Dependence Scale) scores. 
Sequence variations in nicotinic acetylcholine receptor 
subunit genes seem to be associated with alcohol and other 
substance dependence. Sherva and colleagues reported two 
SNPs associated with alcohol dependence: rs615470 in 
Chrna5 and rs578776 in Chrna3 [102]. 
GENOME-WIDE ASSOCIATION STUDIES (GWAS) 
Alcohol dependence is a complex disorder and the con-
tribution of single genes and variations to the clinical pheno-
types of addictive behavior is very hard to estimate. Recent 
advances in genotyping tools and the completion of the 
HapMap project are allowing a comprehensive genome 
mapping of SNPs and the possibility of hypothesis-free iden-
tification of genes that contribute to the risk of polygenic 
diseases. Genome wide analysis of variants concurring to 
increased vulnerability for alcohol addiction are constantly 
returning new and unpredictable targets. In the last few years 
a growing number of case-control GWAS studies on alcohol 
addiction have been published and a recent and accurate re-
view of GWAS literature and a meta-analysis of studies 
meeting defined criteria was performed by Zuo and col-
leagues [103]. Since the development of AD has been con-
sidered to be related to alcohol metabolizing enzymes, Adh 
and Aldh are considered as candidate genes. Similarly AD 
has been reputed a brain disease and genes related to neuro-
transmitters are as well considered as strong candidates. All 
of these hypotheses helped in finding many risk genes for 
alcohol dependence, as reviewed above. The GWASs, over-
coming the necessity of an a priori hypothesis, besides con-
firming the ADH cluster as the most robust risk locus, gave 
back many different targets. Serinc2, Kiaa0040, Nrd1 and 
Htr7 emerged as important risk loci related to the develop-
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ment of AD. Pknox2, Mreg, Pecr, Gpd1l, Cmtm8, Map3k9, 
Pcnx, and Opa3 seem to be, to a lesser extent, involved in 
risk for this disease. Analysis approaches typically used by 
genome wide studies consider the effect of every single SNP 
individually. In the presence of a large effect size, when a 
sequence variation heavily affects protein function, it is quite 
easy to detect an association with the disease and its patho-
genetic processes. However, when multiple sequence varia-
tions contribute to the phenotype each with a small effect, as 
happens for alcoholism and other multifactorial disease, it is 
not suitable to assess the effect of every single variation in-
dividually. The analysis strategy applied in some GWAS 
[90,104,105], that returned no genome-wide significant asso-
ciation findings, denote a limited power to identify SNPs 
associated to AD. This reduced detection power can be at-
tributed to the need for even larger sample sizes and more 
powerful statistical methods to identify the complex interac-
tions between multiple genetic variations that contribute to 
the risk of complex diseases like alcoholism. Preliminary 
hypothesis about the power of the alleles and their frequency 
in the population are requested to deal with the complex cal-
culation of the sample size for a GWAS [106]. Usually the 
most significant SNPs emerging from a GWAS are to be 
retested in an independent sample, and while it has been ini-
tially proposed that a p value of 10
-5
 was enough to survive 
retesting, it is now commonly believed that at least a p value 
of 10
-8
 is required. Furthermore, sample sizes required to 
have 90% power to repeat the findings of a previous GWAS 
at a p value threshold of 10
-8
 have been calculated, with the 
strongest association that needs at least 2500 cases and con-
trols to be confirmed, as assessed by Altshuler and Daly 
[107]. Technologies utilized in GWAS can simultaneously 
deal with a large number of variations but are not able to 
measure every known SNP. Genotyped SNPs, acting as tag-
ging SNPs, because of linkage disequilibrium, should then 
predict the majority of the rest of the SNPs. A SNP that con-
fers a small increased relative risk of disease, small enough 
and not be removed by selection pressure, should be seen at 
a higher rate in probands affected by the disease. High-risk 
alleles, each individually rare, “recently” arisen at random 
adjacent to a SNP that is not a disease allele, are not detected 
in a GWAS. The SNP genotype, not being related to the dis-
ease, leaves the frequency of the tagging SNP alleles the 
same in cases and controls. Therefore, it seems quite clear 
that only common, disease-associated, variants should be 
detected by GWAS. The theory known as common dis-
ease\common variant (CDCV) [108] supports the idea that 
genetic variants with an appreciable frequency in the general 
population but a limited risk ratio (of approximately 1.2-2) 
are the major contributors to genetic susceptibility to com-
mon diseases. On the other hand, the common disease\rare 
variant (CDRV) [108] hypothesis shifts the responsibility 
towards multiple rare DNA sequence variations, each with 
relatively high penetrance, as the major contributors to ge-
netic susceptibility to common diseases. Each of these hy-
potheses is taken into consideration in current studies. 
PERSONALIZED MOLECULAR TREATMENT OF 
ALCHOL USE DISORDERS 
In Table 6 a list of the sequence variations, involved in 
pharmacogenetics of AD, is produced. 
Pharmacological Molecules Acting on Serotoninergic 
Transmission 
As previously mentioned, the 5HTTLPR polymorphism 
has been studied indepth in relation to susceptibility to alco-
hol abuse and dependence, but it can work in a synergistic 
way with other sequence variations modulating the response 
to pharmacological treatments that target the serotoninergic 
system. Alcoholic subjects with 5-HTTLPR L/L and 
rs1042173 T/T genotype have a great response to therapy 
with ondansetron, a serotonin 5-HT3 receptor antagonist, in 
terms of fewer mean drinks per drinking day and a higher 
percentage of days abstinent compared to all the other geno-
types [34]. Furthermore, in a recent paper, a panel of five 
markers has been introduced, combining the variations pre-
viously reported in Slc6a4 (5HTTLPR and rs1042173) with 
polymorphisms in the Htr3a (rs1150226 and rs1176713) and 
Htr3b (rs17614942) genes, that can be used to give a better 
prediction for the outcome of therapy with Ondansetron in 
AD subjects [109]. The tri-allelic polymorphism (5HTTLPR 
and rs25531 A to G polymorphism) can also be used to drive 
pharmacological therapy. Late onset alcoholics homozygotes 
for the LA allele, take advantages using the SSRI sertraline 
that reduces, only in these subjects, heavy drinking and 
drinking days per week, the positive effects of sertraline per-
sisting for three months after pharmacologic treatment 
[110,111].  
Agents Acting on Dopaminergic System 
The long allele (seven repeats or more) of Drd4 VNTR 
polymorphism seems to have a moderating effect on the 
pharmacologic response to μ opioid receptor antagonist 
Naltrexone as shown in the study by Tidey and colleagues 
[112]: heavy drinkers with Drd4 L/L genotype reduced the 
percentage of heavy drinking days when treated with 
Naltrexone (50 mg) and this result was found to be inde-
pendent from the genotype of the Oprm1 gene c.118A>G 
(rs1799971) polymorphism. The Drd4 VNTR polymorphism 
was also found to regulate the efficacy of Olanzapine, a 
D2/5HT2 receptor blocker [113]. In a clinical trial in which 5 
mg of Olanzapine were administered to AD subjects, craving 
was reduced in those carrying the Drd4 L/L genotype, 
moreover, a reduction in the number of drinks per drinking 
days and a reduced number of drinks in general was also 
observed. 
Naltrexone and Opioidergic Transmission 
The Oprm1 gene Asn40Asp polymorphism has an impor-
tant role in the pharmacological treatment of AD. The opioid 
receptor antagonist Naltrexone (with a prevalent action on μ 
and ? receptors) is commonly used in the therapy of alcohol-
ism although with moderate effects. The pharmacogenetics 
of Naltrexone identifies individuals with a better response to 
this medication on the basis of their genetic background 
[114]. The response to Naltrexone, in AD subjects in clinical 
trials [115,116] was found to be conditioned by the 
c.118A>G Oprm1 polymorphism. The presence of at least an 
Asp40 (G) allele has been associated with a lower relapse 
rate and a slower return to heavy drinking. These results 
have been consolidated in a larger sample from the Combin-
ing Medications and Behavioral Interventions for Alcohol- 
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Table 6. Sequence variations with a pharmacogenetic effect on pharmacological treatments for AD.  
Medications Gene 
Genetic  
Variants (rs) 
Nucleotide 
Change 
(Forward 
Strand) 
Aminoacid 
Change 
(Codon) 
Allelic Frequencies 
(Overall, 1000 
Genomes) 
Pharmacogenetic Findings* 
5-HTTLPR n. c. n. c. - 
Slc6a4 
rs1042173 A/C n. c. A (0.49)/C (0.51) 
rs1150226 A/G n. c. A (0.11)/G (0.89) 
Htr3a 
rs1176713 A/G n. c. A (0.74)/G (0.26) 
Ondansetron 
Htr3b rs17614942 C/A n. c. C (0.94)/A (0.06) 
AD individuals carrying one or more of 
genotypes rs1150226-A/G and 
rs1176713-G/G in Htr3a and 
rs17614942-A/C in Htr3b combined 
with 5-HTTLPR-L/L and rs1042173-
T/T genotype have a great response to 
therapy with ondansetron. 
5-HTTLPR n. c. n. c. - 
Sertraline Slc6a4 
rs25531 T/C n. c. T (0.89)/C (0.11) 
Late onset alcoholics homozygotes for 
the LA allele, take advantages using the 
SSRI sertraline that reduces, only in 
these subjects, heavy drinking and 
drinking days per week. 
Drd4 DRD4 VNTR n. c. n. c. - 
Heavy drinkers with Drd4-L genotype 
reduced the percentage of heavy drink-
ing days when treated with Naltrexone.  
Naltrexone 
Oprm1 rs1799971 A/G p.Asn40Asp A (0.81)/G (0.19) 
The response to Naltrexone, in AD 
subjects in clinical trials was found to be 
conditioned by the A118G Oprm1 
polymorphism; the presence of at least 
an Asp40 (G) allele has been associated 
with a lower relapse rate and a slower 
return to heavy drinking. 
Olanzapine Drd4 DRD4 VNTR n. c. n. c. - 
In AD subjects assuming of Olanzapine, 
craving was reduced in those carrying 
the Drd4 L/L genotype; moreover, a 
reduction of the number of drinks per 
drinking days and a reduced number of 
drinks in general was also observed. 
*See text for references; n. c.= no change 
 
ism (COMBINE) study [116], although the work by Gelern-
ter et al. has failed to find this modulating role of the poly-
morphism [117]. Ray and colleagues [118] have presented 
another feature of the interaction between genotype and opi-
ate antagonist naltrexone: the presence of the Asp40 allele 
contributes to trigger a biobehavioral mechanism that re-
duces the subjective reaction to alcohol through the dampen-
ing of the alcohol “high” and produces the clinical pharma-
cogenetic effect. Recently a systematic review and meta 
analysis of six prospective studies has confirmed the lower 
relapse rate, previously observed, in AD patients carrying at 
least a G allele and treated with Naltrexone [119].  
CONCLUSION, OPEN ISSUES AND FUTURE PROS-
PECTS 
The findings reported in this review constitute a sum-
mary of the state-of-the-art of the molecular basis of AD. 
They constitute the best fundamental knowledge at moment 
available for a molecular biology-based diagnostic and 
therapeutic approaches of AD. However, although current 
research on the genetics of AD have shed lights on many 
interesting molecular targets, in terms of risk genes and mo-
lecular markers for pharmacological therapy, still more 
needs to be done to deeply understand the genetics of alcohol 
use disorders. This also depends on the fact that not all alco-
holics share an identical background: different social and 
environmental circumstances act on different and multiple 
genetic substrates. Maybe this challenge should be faced in a 
different and possibly omni-comprehensive way. Case con-
trol studies often take into consideration only a limited num-
ber of polymorphic sites at the same time that are known (or 
supposed) to modulate the efficiency of certain pathways, 
but multiple variations, occurring in the same or in other 
genes, can modulate the effect of the single or the few poly-
morphisms evaluated. The small effect of a single variation 
should be counterbalanced by other polymorphisms simulta-
neously present and this is true e.g. for the serotonin trans-
porter where a consistent number of polymorphic sites, with 
opposite effects on expression or protein function, are de-
scribed and characterized. Moreover, the serotonin trans-
porter is only one of the key points of serotonin transmis-
sion. The serotoninergic neuron possesses many other phar-
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macological targets that represent as many points of control 
of 5-HT transmission and each point can be affected, at a 
genetic level, by polymorphic regions that might regulate the 
efficiency of every single passage. These “check points” may 
be the captation of tryptophan, the hydroxylation of L-
tryptophan in 5-hydroxy-tryptophan and so on up to the 
postsynaptic receptors and their signal transmission path-
ways when present. Every one of these passages can be 
modulated by DNA sequence variations. Furthermore, the 
risk of assessing a possible association in the wrong way can 
occur for other important reasons. A proper classification of 
cases and an accurate selection of controls should be done, in 
particular for alcohol dependent patients where, at least in 
half of the individuals, psychiatric comorbidities exist and 
often also a multi-drug dependence. The allelic frequencies 
of single nucleotide polymorphisms are variable among dif-
ferent populations and this should also be considered. The 
differences between the target and the control population 
could be, in this way, minimized, leading to an erroneous 
evaluation that could also be one of the reasons for the con-
trasting literature that is often found in association studies. In 
the light of these facts it is very difficult to elaborate theories 
based on a single or a small group of polymorphisms ana-
lyzed. In the GWAS strategy the power to detect associations 
can be different from gene to gene because of the non homo-
geneous coverage of genes by SNPs on GWAS arrays. The 
specific human population being studied and the SNPs se-
lected for the assay by each platform require careful consid-
eration. As an example, african genomes have had more time 
to recombine than Europeans, so they have less linkage dise-
quilibrium between alleles at different SNPs and therefore it 
is important to use a chip that has more SNPs with better 
overall genomic coverage to study Africans. Other limita-
tions are that chip-based microarray technology for assaying 
a million or more SNPs usually do not include other types of 
variations such as variable number of tandem repeat poly-
morphisms or copy number variations. One possible alterna-
tive approach is to use an entire gene set as a single entity to 
test for association with the phenotype of interest. Limita-
tions of this kind of studies include, as happens for candidate 
gene studies, the reliance on a priori hypothesis as well as 
the knowledge of relevant biological pathways associated 
with the phenotypes of interest. Chip-based genotyping plat-
forms will probably be replaced over the next few years with 
next generation sequencing (NGS) based techniques that are 
slowly reaching cost effectiveness. Exome sequencing, RNA 
sequencing and bisulfite DNA sequencing as well as whole 
genome sequencing NGS based, will soon provide concrete 
answers about the role of point mutations as well as other 
variants in alcohol dependence. Comparing whole genomes 
from a control and a target population will help to shed light 
not only on molecular mechanisms already known, but also 
to discover new and maybe unexpected molecular targets. 
Furthermore, the role of epigenetic processes in brain gene 
expression after chronic alcohol exposure is a growing and 
attractive field of study. Changes in methylation of DNA and 
histones, microRNA driven gene expression, acetylation and 
de-acetylation of histone proteins are associated to brain 
plasticity and to the development of pathologic processes 
involved in alcohol abuse and addiction. In the immediate 
future, epigenetics will probably represent the most rapid 
growing field within molecular mechanisms of acohol addic-
tion. 
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